In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Innovex to co-promote CV Therapeutics' angina drug

Executive Summary

In the US, Quintiles Transnational Corp's Innovex contract sales division will market and sell CV Therapeutics' Phase III angina therapeutic ranolazine. Innovex bought (uf)$5mm of CVT common stock, will make a $10mm milestone payment when the drug is FDA approved, and offer a $10mm line of credit, which it could convert into CVT common stock at its option.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies